Pharmacologic class (EPC) · 10 drug pages

Vascular endothelial growth factor inhibitor: adverse event reports filed with FDA

176,429 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

176,429
reports across the class: 0.9% of all reports; 10,792
reports, 12 months to June 2026: 11,190 in the 12 months before; 87.6%
marked serious by the reporter: 57.4% across all reports; 10
drugs with a page: brand and generic names counted separately

Vascular endothelial growth factor inhibitor is a pharmacologic class (an FDA Established Pharmacologic Class) with 10 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 176,429 adverse event reports received by FDA, 0.9% of the database, from January 2004 to June 2026.

10,792 reports arrived in the 12 months to June 2026, close to the 11,190 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 87.6% of the class's reports are marked serious, 23.7% record death among the outcomes and 26.9% record hospitalisation, as reported.

Across the class the reactions recorded most often are death (14.1%), off label use (9.8%) and disease progression (4.5%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
AvastinBevacizumab	brand	60,510	2,198	87.3%	Death
Bevacizumab	generic	54,611	6,049	96.4%	Off label use
EyleaAflibercept	brand	25,826	968	81.5%	Death
LucentisRanibizumab	brand	20,417	203	82.9%	Death
Ranibizumab	generic	4,862	119	97.4%	Visual acuity reduced
MvasiBevacizumab-awwb	brand	4,508	542	27.9%	Off label use
Aflibercept	generic	2,772	227	97.3%	Diarrhoea
ZaltrapZiv-aflibercept	brand	1,227	22	93.3%	Diarrhoea
Eylea HdAflibercept	brand	1,091	411	66.8%	Visual impairment
ZirabevBevacizumab-bvzr	brand	605	53	81%	Off label use

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Deaththe patient died; cause not stated by this term14.1%24,881
Off label useused for a purpose or in a way not on the label9.8%17,320
Disease progressionthe disease advanced4.5%7,974
Diarrhoealoose or frequent stools4.4%7,710
Hypertensionhigh blood pressure3.8%6,781
Fatiguetiredness3.7%6,592
Nauseafeeling sick3.7%6,571
Drug ineffectivethe medicine did not work as expected2.9%5,121
Vomitingbeing sick2.9%5,043
Visual acuity reducedreduced sharpness of vision2.7%4,791
Visual impairmentreduced vision2.6%4,598
Anaemialow red blood cells2.5%4,422
Pyrexiafever2.4%4,153
Neutropenialow neutrophils, a type of white blood cell2.3%4,128
Astheniaweakness or lack of energy2.2%3,876
Dyspnoeashortness of breath2%3,518
Blindnessloss of sight2%3,505
Decreased appetitereduced appetite2%3,482
Endophthalmitisinfection inside the eye1.9%3,336
No adverse eventno adverse event was reported1.9%3,283
Thrombocytopenialow platelets1.9%3,282
Proteinuriaprotein in the urine1.8%3,233
Headachehead pain1.8%3,116
Abdominal painstomach or belly pain1.7%2,996
Neuropathy peripheralnerve damage in hands or feet1.6%2,888

Solid bar: share of all class reports. Hollow bar: the median share across the 10 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death23.7%41,762

Life-threatening3.6%6,341

Hospitalisation (initial or prolonged)26.9%47,521

Disability2.8%4,882

Congenital anomaly0%55

Other serious53.8%94,927

Not serious12.4%21,921

Patient age

Under 20.1%227

2 to 110.4%700

12 to 170.3%477

18 to 444.2%7,454

45 to 6419.4%34,182

65 to 7414.5%25,543

75 and over11.9%20,919

Age not given49.3%86,927

Who reported

Physician44%77,680

Pharmacist5.4%9,532

Other health professional23.9%42,084

Lawyer0%86

Consumer or non-health professional24.9%43,870

Not given1.8%3,177

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Vascular endothelial growth factor inhibitor reports

Which drugs are in the Vascular endothelial growth factor inhibitor class on this site?

Avastin, Bevacizumab, Eylea, Lucentis, Ranibizumab and Mvasi and 4 more. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

176,429 reports through June 2026, 10,792 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

death (14.1%), off label use (9.8%), disease progression (4.5%), diarrhoea (4.4%) and hypertension (3.8%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.